AstraZeneca Sees Strong Oncology-Driven Japan Growth
This article was originally published in PharmAsia News
AstraZeneca sees “very, very good growth” for its Japanese business in the mid-term, driven by newer already launched drugs, a full local pipeline and an expected two product launches a year over the period to 2020.
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.